The passage of a vascular-injected paramagnetic contrast reagent (CR) bolus through a region-of-interest affects tissue 1 H2O relaxation and thus MR image intensity. For longitudinal relaxation [R1 ϵ (T1) ؊1 ], the CR must have transient molecular interactions with water. Because the CR and water molecules are never uniformly distributed in the histological-scale tissue compartments, the kinetics of equilibrium water compartmental interchange are competitive. In particular, the condition of the equilibrium transcytolemmal water exchange NMR system sorties through different domains as the interstitial CR concentration, [CRo], waxes and wanes. Before CR, the system is in the fast-exchange-limit (FXL). Very soon after CRo arrival, it enters the fast-exchange-regime (FXR). Near maximal [CRo], the system could enter even the slowexchange-regime (SXR). These conditions are defined herein, and a comprehensive description of how they affect quantitative pharmacokinetic analyses is presented. Data are analyzed from a population of 22 patients initially screened suspicious for breast cancer. After participating in our study, the subjects underwent biopsy/pathology procedures and only 7 (32%) were found to have malignancies. The transient departure from FXL to FXR (and apparently not SXR) is significant in only the malignant tumors, presumably because of angiogenic capillary leakiness. Thus, if accepted, this analysis would have prevented the 68% of the biopsies that proved benign.
field. We refer to such paradigms as members of the standard model (SM) family. However, these formalisms were developed for tracer pharmacokinetics, with the intrinsic feature of direct radiotracer detection. Although the MRI CR plays the tracer role, the signal molecule remains water, which is differently distributed. The direct application of tracer pharmacokinetic models to MRI data (1) resulted in the inadvertent constraint that all intercompartmental equilibrium water exchange be treated as if infinitely fast. This corollary is not valid (2, 6) , and its assumption can effectively short circuit MRI determination of CR compartmentalization (2, 7)-the pharmacokinetic essence. In a series of papers (2, 5, 6, (8) (9) (10) (11) (12) (13) (14) (15) (16) , we have examined the significance of this implication. We refer to models incorporating equilibrium exchange effects in the pharmacokinetic derivation as belonging to the shutter-speed model (SSM) family.
Here, we survey the effects of intercompartmental water exchange kinetics in DCE-MRI breast cancer screening. They appear to facilitate discrimination of benign and malignant lesions, as we show here and in a companion paper (17) . 
Results
where S is the signal intensity and S 0 is that for the sample Boltzmann 1 H 2 O magnetization (M 0 ). The symbols S are saturation (really unsaturation) factors (18) . Eq. 1 recognizes that each tissue signal comprises potentially separable intracellular, interstitial, and blood compartmental 1 Eq. 1 recognizes that the tissue 1 H 2 O signal can potentially exhibit triple-exponential longitudinal relaxation. This possibility is accommodated with a 3 ϫ 3 exchange matrix accounting for equilibrium water exchange between blood and interstitium and between interstitium and cytoplasm-a 3-site 2-exchange (3S2X) system (2) . But it is cumbersome to write nonmatrix algebraic expressions for the apparent compartmental quantity (pЈ i , R 1 Ј i , pЈ o , R 1 Ј o , pЈ b , and R 1 Ј b ) time-dependencies during CR pharmacokinetic passage in terms of the more fundamental intrinsic compartmental properties containing pathophysiological information.
Eliminating the often small blood term (i.e., let pЈ b S b 3 0), on the right-hand side of Eq. 1 leaves a 2-site-exchange (2SX) system, for equilibrium water transcytolemmal interchange. But, nonmatrix algebraic expressions for the pЈ i , R 1 Ј i , pЈ o , and R 1 Ј o would still be cumbersome (19) . However, there are simpler nonmatrix 2SX equations with phenomenological bases. We have presented (18) a version of Eq. 2,
where the notation is that of Eq. 1 except, instead of i and o subscripts, there are L and S subscripts (the primes are unnecessary), which distinguish 2 empirical exponential components with larger and smaller T 1 values, T 1L and T 1S , respectively (thus, )}, where ␣ is the flip angle, TR and TE are the repetition and echo times, and R 2 ‫ء‬ is the apparent transverse relaxation rate constant.] Ref. 5 
] that the system is in the fastexchange-limit (FXL) condition. This situation is tantamount to stating that S/S 0 is ͗pЈS͘ or ͗aS͘ on the right-hand sides of Eqs. 1 and 2, respectively. As CR o arrives and increases, the system departs the FXL for the fast-exchange-regime (FXR) condition, which we (5) defined to be the situation when the a S S S term on the right-hand side of Eq. 2 (vanished in the FXL) remains negligible. A significant contribution from the a S S S term defines the slow-exchange-regime (SXR) condition (5) . As CR o washes out of the tissue, this progression is reversed. Although cell suspension systems can be driven to the FXR, the SXR, and even the slow-exchange-limit (SXL) (Exchange Domains in SI Text), there has never been conclusive evidence for a tissue system reaching the SXR in a DCE-MRI study.
We conducted a number of different pharmacokinetic analyses here. The SM assumes that the equilibrium water intercompartmental exchange systems remain in the FXL: it is FXLconstrained (FXL-c). We also used the FXR-and SXR-allowed (FXR-a and SXR-a) versions of the first-generation ShutterSpeed Model (SSM1), BOLus Enhanced Relaxation Overview (BOLERO) (8, 11) . In the SM analyses, the parameters varied are K trans and v e , while the i value is (implicitly) zero (11, 13, 14) .
[K trans measures the CR extra/intravasation rate (Theory in SI Text).] In some SSM analyses, i is also varied. The complete 9-parameter set has been tabulated (14) and the constant values of the other parameters have been reported (13, 14) .
MRI Data. Data were obtained with consent from patients with positive mammographic and/or clinical MRI reports from standard institutional breast cancer work-ups and protocols. All had MRI contrast-enhanced lesions radiologically classified as Breast Imaging Reporting and Data System (BIRADS) four (B-4, suspicious) or five (B-5, highly suggestive of malignancy) (17) . Emphasizing practicability and robustness, the data are of a rather routine clinical nature (they were obtained at 2 different institutions, with 2 different instruments, CRs, etc.): The 2 different data acquisitions were by no means optimized for quantitative DCE-MRI. For example, the pulse sequence parameters were prescribed by radiological spatial resolution and tissue volume coverage considerations because many images were to be used to guide immediately subsequent surgical interventions. The pharmacokinetic period is truncated, and although the spatial resolution is reasonable, the temporal resolution is not optimal. Also, the adipose tissue -1 H 2 C-MR signal is suppressed in only one institution's acquisitions. Fig. 1A shows the 3.3-min pharmacokinetic image of sagittal slice 20 (from lateral to medial) of a 57-year-old subject's left breast [patient 4 (17) ]. The ROI marked represents 17 pixels (10 mm 2 , 31 L) containing the tiny lesion evident in this slice, subsequently found to contain both malignant invasive and in situ ductal carcinoma (IDC/DCIS). Fig. 1C shows the 3.6-min pharmacokinetic image of slice 12 of a 52-year-old subject's left breast [patient 8 (17) ]. The ROI there represents 164 pixels (81 mm 2 , 243 L) containing the lesion evident in this slice, subsequently found to comprise benign lobular carcinoma in situ and stromal fibrosis (LCIS/SF). These images were acquired with adipose -1 H 2 C-suppression (institutional protocol required). In contrast to those (13, 14) obtained with no fat suppression, these darker images show glandular regions brighter than fatty tissues. The 1 H 2 O S/S pre time courses for these 2 ROIs are shown in Fig. 1 B and D (circles) . The CR injection timing is suggested by the rectangular function below the Fig. 1D abscissa. The shape of the IDC/DCIS ROI data (Fig. 1B) is that often reported as characteristic of such tumors: much faster and greater uptake (followed by washout) compared with a benign lesion such as that of Fig. 1D (13, (20) (21) (22) (23) (Fig. 1D Inset) .
There are many traces in Fig. 1 B and D. Three curves each are fitted to the IDC/DCIS ROI data and the LCIS/SF ROI data. The black dashed curve distinguishable in Fig. 1B represents the best FXL-c (SM) fitting of the data. The model has the constraints that i is vanishingly small (the FXL) and that the transverse relaxation factor [exp(ϪTE⅐R 2 ‫ء‬ )] ϭ 1. The dashed curve shows the characteristic undershoot at the beginning, followed by overshoot and then undershoot during the washout (11, 13, 14 There are 4 additional dotted curves (blue and red pairs) each in Fig. 1 B and D. The top member of each pair represents the FXL ( i 3 0) expectation for the FXR-a (blue) and for the SXR-a (red) Table 1 parameter values. The bottom members represent the corresponding no-exchange-limit (NXL) ( i 3 ϱ) expectations. Thus, the vertical dynamic range between the top and bottom members of a pair is a measure of the model exchange sensitivity for this acquisition of these data. This property is not the same as the shutter-speed. The greater difference between the top blue curve and the data for the malignant IDC/DCIS (Fig. 1B ) than for the benign LCIS/SF (Fig. 1D) tumor. This mismatch was also seen in the comparison of an IDC with a benign fibroadenoma (figure 1b and d of ref. 13 ). This observation is a preview of the FXR-a analysis ability to discriminate malignant from benign breast tumors. The only way the FXL-c (SM) model can bring the blue dotted curve down to the data circles is by reducing parameter values below those for the FXR-a fitting. Although the SM comes close to matching the data for the benign lesion, it fails much more significantly for the malignant tumor-just when needed.
The NXL expectation for the FXR-a parameters (bottom blue dotted line) shows no S/S pre change during the CR bolus passage.
and R 1L 3 R 1i , as they must (R 1S Ͼ R 1L ). Thus, in this limit, R 1L ϭ R 1i , which is [CR o ]-independent, and because there is only S L for the FXR-a Eq. 2 version, S is constant. The exchange sensitivity for analysis by the FXR-a version (blue curves) is necessarily greater than that for analysis of the same data by the SXR-a version (red curves). One way to understand this maxim is by inspecting theoretical putative calibration curves implicit in the analyses [Calibration Curves in SI Text]. Before CR o arrival, a S is zero and R 1L is p i R 1i ϩ p o R 1o : the FXL. When CR o first arrives, a S grows only very slowly: the FXR condition obtains until its contribution becomes significant (5, 18) .
However, it is very interesting that the However, most of the benign lesions (11 of the 15 total) exhibited the same upper bound indeterminacy as the malignant tumor in this regard. The FXR-a calibration curves (SI Text) imply that there will be greater parameter value differences between FXL-c (SM) and FXR-a (SSM) analyses. This result is seen in Table 1 . For the IDC/DCIS data, FXR-a analysis increases v e by more than 2-fold and K trans by 38%. If i is let float, FXR-a analysis returns a value of 360 (Ϯ 58) ms (SD) (with no K trans change and an 8% v e decrease), which is very reasonable (as we will see below).
Ostensibly, the SXR-a model includes the FXR-a model. However, the results suggest that the SXR-a model is less compatible with the data, an indication of systematic error. We will discuss possible reasons for this below. We now present the results for analyses of the data from all of the lesions by using the FXL-c SM and the FXR-a SSM. As we will see, these breast screening DCE-MRI data seem quite compatible with FXR-a analyses.
Comparison of Pharmacokinetic Model and Gold Standard Pathology
Analyses. For each of the 22 patients, 2 investigators independently analyzed ROI data from 1 sagittal image slice (of 16 to 40 per breast) exhibiting a lesion biopsied only post-DCE. They were each blinded to the biopsy pathology reports. An ROI boundary was independently manually drawn around the entire lesion in a pharmacokinetic image showing near maximal enhancement. The results of 2 different pharmacokinetic analyses (FXL-c and FXR-a) of the DCE-MRI data from the 22 lesion ROIs by each investigator were then averaged lesion-by-lesion, model-by-model, and parameter-by-parameter. The FXL-c analyses varied K trans and v e , whereas the FXR-a analyses also varied i . It is obvious that none of the SM parameters allows complete separation of the circles (malignant) and triangles (benign). None achieve anywhere near 100% positive predictive value (PPV) (the best is 54%, for SM K trans ). Compared with the SSM, the SM generally underestimates the parameter value [albeit with some precision benefit from reduced parametrization (11, 14) ], except for k ep (Fig. 2D ) and (1 Ϫ v e )/ i (Fig. 2E) . The latter is effectively infinite in the SM. Discussion arguments suggest that these underestimations are in the absolute sense. Importantly, in the K trans and K trans /v e ( Fig. 2 A and D) cases, it is the SM misestimation that prevents better separation of circles and triangles achieved by the SSM (70% PPV for each). For the K trans parameter (Fig. 2 A) , the SM underestimation has occurred in only malignant tumor ROIs (circles). [These include the Fig. 1 malignant/benign ROI pair (Table 1) , and the only other such pair reported (13) .] One black circle is comingled with the red triangles in the Fig. 2 A SSM column only because of partial volume dilution (17) . For K trans /v e (Fig. 2D) , it is the SM overestimation of particularly benign ROI values that prevents their almost complete separation achieved by the SSM. [The ratio K trans /v e is equal to k ep , the unidirectional CR intravasation rate constant. For passive CR transport, k ep is equal to (v b /v e )k pe (1) ; v b is the tissue blood volume fraction, and k pe is the rate constant for CR extravasation.] These K trans and k ep parameter behaviors are not observed for the SXR-a analyses.
There are several other items of note in Fig. 2 . The SSM v e values are increased in both benign and malignant lesions, and they rise to be quite large in some cases, all but one of them benign (Fig. 2B) . The large v e malignant tumor is mostly benign (17) . Although the malignant and benign i values become finite [and quite reasonable (see below)] with the SSM analyses (Fig.  2C) , they overlap considerably (thus, this behavior does not contribute to discrimination). It is interesting that the benign values tend to be somewhat larger, although less certain. Although i Ϫ1 is proportional to the mean individual cellular claustrophobic ratio [surface area (A) to volume (V)] (6), it also increases with the transcytolemmal water permeability coefficient [ i Ϫ1 ϭ P W (A/V)]. The P W magnitude can reflect the extent of cytolemmal aquaporin expression and/or the cellular metabolic status. The ratio ( 
where v i is the tissue intracellular volume fraction and SЈ is the total cell surface area per voxel volume. P W SЈ is considered infinitely large by the SM. When P W SЈ is calculated by the SSM, the benign tumor values cluster considerably around 1.1 s Ϫ1 and the malignant tumors around 1.3 s Ϫ1 (Fig. 2E) . Even more remarkable clustering is seen for the SSM benign k ep values, near 0.15 min Ϫ1 (Fig. 2D) . This finding reinforces the common notion of considerably greater heterogeneity in malignant tumors. It also means that, although the SSM v e values show considerable scatter (and no discriminatory power) (Fig. 2B) , they are well correlated with the SSM K trans values; see the companion paper (17).
Discussion
The Fig. 2 A results It is particularly the i aspects of applying the SXR-a SSM version to the malignant tumor data that suggest SXR-a incompatibility. As stated above, for 86% of the malignant tumor and 73% of the benign lesion ROIs, SXR-a analyses floating i increased its value until the program incrementation limit was reached. In most cases, the upper bound allowed was 40 s. Fig.  1B shows that the IDC/DCIS data points are on the (red) NXL curve for the SXR-a model. As far as SXR-a analyses are concerned, i 3 ϱ for these breast tumors. This extreme is unreasonable and cannot be attributed to only i uncertainty.
Thus, the cumulative weight of the literature results cited and our own results suggests that the FXR-a analyses yield reasonable pharmacokinetic parameter values when the SXR-a analyses do not. Why might that be?
One possibility is that none of the many diverse biological systems studied in the literature proceed sufficiently to depart the FXR for the SXR. However, if so, SXR-a analyses would give the same results as FXR-a analyses, because the former differs only if the SXR condition is reached.
A second possibility lies in the way the FXR-a analyses are performed. At each pharmacokinetic time point, the (extensive) signal intensity is used to estimate the (intensive) R 1L valuebecause there is only the S L factor on the right-hand side of Eq. 2. Then, it is the R 1L time-dependence that is fitted. This operation may effectively unweight any contribution from an actual a S S S term. Because there is only a single recovery time point (at TR), this seems a particularly parsimonious approach.
A third possibility is that the SXR-a analyses overestimate the S S factor contribution, which could be disproportionately quenched by transverse relaxation. 
Conclusions
The DCE-MRI acquisitions for these data, prescribed for radiological considerations, were not particularly exchange sensitive. Even so, exchange effects seem to facilitate very high discrimination of malignant from benign breast tumors (17) . In recent years, there has been considerable effort devoted to decreasing DCE-MRI pulse sequence exchange sensitivity (25) . Our results suggest that there could be significant profit, not the least for cancer screening, in working to increase exchange sensitivity, by adjusting not only ␣ and TR, but also TE (a small increase may improve specificity). The considerations expressed here could guide such endeavors.
Materials and Methods
Details on some of the MRI data acquisitions and analyses have been published (13, 14) ; more particulars and differences are presented here.
Patients. Twenty-two patients were recruited from clinical breast cancer populations that had undergone initial screening (mammographic and/or clinical breast MRI protocols) at 2 different institutions: Stony Brook (SB) and Sloan-Kettering (SK). All were placed in the B-4 (n ϭ 17) or B-5 (n ϭ 5) classifications, which were to lead to biopsy procedures. Numerous details on the subjects are given in the companion paper (17) .
DCE-MRI Data Acquisition.
The study was conducted using 2 different 1.5-T MR systems [Edge (Philips/Marconi), SB; Excite (General Electric), SK] with body radiofrequency transmit coils, and 4-(SB and SK) and 7-channel (SK) phasedarray, prone patient, bilateral breast radiofrequency receive coils having compression plates. A 3D SPGR pulse sequence was used to acquire 12-20 serial sagittal image volume sets continually, covering the entire breast with the suspicious lesion to be biopsied. Other parameters included 10°(SK) and 30°fl ip angles, 3-to 4-ms TE, 6-to 9-ms TR, 3-mm section thickness, 18-to 24-cm field of view, and 256 ϫ 128 and 256 ϫ 64 (SB) matrix sizes, zero-filled to 256 ϫ 256 during image reconstruction. The SK acquisitions suppressed the fat -1 H2C-signal with narrow-band saturation radiofrequency pulses centered on its value. The phase-encoding direction was superior/inferior. Depending on the breast size, each volume set contained 16 -32 image sections, resulting in 13-to 28-s temporal resolutions. At the start of the second volume set acquisition, the CR [gadolinium diethylenetriamine pentaacetate bismethylamide (GdDTPA-BMA) (Omniscan; Nycomed), SB; GdDTPA 2Ϫ (Magnevist; Berlex), SK] was delivered via an antecubital vein (0.1 mmol/kg at 2 mL/s) and followed by a saline flush, using programmable power injectors (Spectris; Medrad).
DCE-MRI Pharmacokinetic
Analyses. An ROI was manually drawn within an axillary artery visible in 3D volume image slices. This region was used for AIF determination. For each of the 6 SB patients, the representative AIF from one of them was used. This trace is shown in figures 1 of refs. 13 and 14. Individual AIF time courses were measured for 3 different SK patients. A mean AIF time course (Fig. 1D Inset) was generated by simply averaging these trajectories and used for each of the 16 SK subjects. These AIF time-course data were interpolated by using a 7-parameter empirical expression (11) . For each patient, an ROI was manually drawn to circumscribe the entire enhanced lesion in a DCE-MRI image exhibiting near maximal enhancement. The mean tumor tissue 1 H2O ROI DCE signal intensity/AIF time-course pairs were then subjected to both SM (FXL-c) and SSM (FXR-a) pharmacokinetic analyses to extract K trans , ve, and i (SSM only) parameter values. Many details of the SM and SSM pharmacokinetic modeling of time-course data are described above, and some images from the 6 SB subjects (3 malignant and 3 benign tumors) have been reported (13, 14) . family (1, 2) . Unlike classic inversion-or saturation-recovery (IR, SR) acquisitions, some attempt ''reading'' magnetization even during a nominal single longitudinal relaxation period (1, 3, 4 ) Nonetheless, they still tend to require significant sampling times, and thereby limit pharmacokinetic spatiotemporal resolution and/or the volume coverage of the tissue of interest.
Supporting Information
The other acquisition family features radiofrequency and gradient pulse trains establishing ''Ernstian'' MR steady-states and acquisitions that monitor the pharmacokinetic variation of these. We call this the Steady-State family. Its members can feature quite small sampling times, yielding good spatiotemporal resolution and/or volume coverage.
Although there has been a significant evolution of increasingly efficient Quantitative T 1 sequences (5), these are rarely used for clinically-oriented human DCE-MRI studies, where sampling time constraints are severe. For the latter, MR Steady-State acquisitions are almost universally used. A very common example, and that used here, is the SPGR (SPoiled Gradient-Recalled) sequence. Since only a single TR value is used in these, it is not possible to tell directly whether the 1 H 2 O signal at any particular time in the DCE-MRI time-course has 2 or 3 longitudinal relaxation exponential components ( Eqs. 1, 2, S1, S2 ).
Theory. The magnetization saturation factors of Eq. 1 in the main text are expressed in Eq. S1.
The subscripts 1 and 2 designate longitudinal and transverse relaxation, respectively, and the E factors are defined in Eqs. S2 and S3.
The prime and * superscripts represent the apparent compartmental 1 H 2 O relaxation rate constants. The quantities ␣, TR, and TE are the sequence read pulse flip angle, repetition, and echo times, respectively.
The Bloch longitudinal NMR relaxation rate law was modified for isochronous 2-site-exchange by Woessner (6), and we (7) expressed this for the R 1L , R 1S , and a S quantities of Eq. 2 of the main text. They are reproduced here in Eqs. S4-S6.
R 1i and R 1o0 are the intra-and extracellular 1 H 2 O relaxation rate constants in the absence of exchange, and CR o for the latter. r 1o and [CR o ] are the interstitial CR relaxivity and concentration, respectively. p i and i are the mole fraction and mean lifetime, respectively, of intracellular water molecules. Consider the square root discriminant in Eqs. S4-S6. When i 3 ϱ, the NXL (no-exchange-limit), all right-hand side terms with i Ϫ1 factors vanish. After taking the square root of the square within the discriminant, one chooses the negative root so that a S 3 (1 Ϫ p i ), R 1S 3 r 1o [CR o ] ϩ R 1o0 , and R 1L 3 R 1i , as they must (R 1S Ͼ R 1L ).
To complete a DCE-MRI analytical model, such MR observation equations must be combined with a pharmacokinetic rate law describing the interchange of CR molecules between the plasma space, CR p , and the interstitial space, CR o . We use the integral rate law (from nuclear medicine) often labeled Kety-Schmidt, also given as Eq. S7
which depends on K trans , the volume fraction rate constant product for CR extra-and intravasation at passive equilibrium, and v e , the interstitial volume fraction. The Eqs. 1 and S1-S3 matrix forms combined with S7 produce the second-generation shutter-speed model (SSM2), or BALDERO (Blood Agent Level Dependent and Extravasation Relaxation Overview) (8) . The combination of Eqs. S1-S6 with S7 gives the first-generation SSM (SSM1), or BOLERO (BOLus Enhanced Relaxation Overview) models (2, 9).
The use of the right-hand side of Eq. 2 (a L S L ϩ a S S S ; identified with the first and second terms of the right-hand side of Eq. 1, pЈ i S i ϩ pЈ o S o ) is the slow-exchange-regime (SXR)-a BOLERO version (9, 10) . The use of only the first right-hand side term of Eq. 2, S L (identified with S i ; pЈ o 3 0, a S 3 0), which dominates at the beginning of, and often throughout, the DCE-MRI time-course is the fast-exchange-regime (FXR)-a BOLERO version (9, 10) . IR, SR, or Quantitative T 1 acquisitions have allowed clear determinations of situations when a S S S is directly detected-i.e., when the equilibrium intercompartmental water exchange system has been driven to the SXR condition. They facilitate experimental determination of whether, within error, the longitudinal relaxation is mono-exponential [fast-exchange-limit (FXL) or FXR] or bi-exponential [SXR, slow-exchange-limit (SXL), or NXL]. There is distinct evidence that SXR (and even SXL) can be reached in cell suspension systems, and this possibility is reviewed in the next section.
Exchange Domains. Equilibrium water exchange between histological-scale compartments has been studied by NMR for some time. (12), and for in vivo rat brain with interstitial RR from direct intracerebroventricular infusion (13) . Clear bi-exponential relaxation is not observed for human endothelial cells in vitro with cytosolic or endosomic RR (14) , for excised, intracellular Mn 2ϩ -loaded myocardial tissue after preperfusing rat hearts ex vivo with modest concentrations of MnCl 2 (15) , for rat thigh muscle in vivo at steady-state extracellular RR perfusion (2, 7), and for human brain in vivo during the first pass (16) and during the wash-out (17) after intravascular bolus RR injection. Each of these latter reports (2, 7, 14-17), however, presents strong evidence for the departure from the FXL for the FXR condition. One can also use extracellular flow relaxivity (18) to raise longitudinal Ϫ1 sufficiently that the equilibrium transcytolemmal water-exchange system reaches even the SXL for microbead-attached HeLa cell pellets (19) .
Calibration Curves. Some sample putative calibration curves implicit in the DCE-MRI pharmacokinetic analyses are shown in supporting information (SI) Fig. S1 as plots of signal intensity (S) versus interstitial CR concentration ([CR o ]) (not the time axis of Fig. 1 in the text) . Parameter values for these particular curves are given in the legend. Some quantities for Fig. S1 a-c are:
, and R 1i ϭ R 1o0 . These would be governed by nature (v e ) and also by the physiological temperature and the magnetic field strength used (r 1 and R 1 parameters). The curves also depend on i , which is determined by nature and the physiological temperature. Six curves are calculated for each panel by using Eqs. S1-S6. The upper dotted (purple) curve results when i 3 0 and is labeled FXL. The lower dotted curves result when i 3 ϱ and are labeled NXL (red and blue for the SXR-a and FXR-a versions, respectively). Three Shutter-Speed Model curves are calculated with i ϭ 370 ms: a L S L ϩ a S S S (SXR-a, black solid curve), a S S S (SXR-a, black dashed curve), and S L (FXR-a, blue solid curve). It makes sense that the SXR-a (black) and FXR-a (blue) traces are always between their respective FXL and NXL limiting curves. In Fig. S1d , v e ϭ 0.65, and i ϭ 400 ms for the black and blue solid curves.
Of course, during a data-fitting procedure, the computer program is incrementing the variable parameters. Because, for the work here, this always involves varying v e , and sometimes also i , these (implicit) calibrations are different for each incrementation.
These curves are independent of the K trans value, which is determined by the integrated time-course and extent of the [CR o ] excursion from left to right and back during the bolus passage. As we have described before (10), the exchange system always starts in the FXL condition, and it enters the FXR condition where the FXR-a (blue) curve departs from the FXL curve (purple dotted), Ϸ0.14 mM in panel a. If the [CR o ] value proceeds past where the SXR-a (black) curve departs from the FXR-a (blue) curve (Ϸ0.3 mM in a), the system has entered the SXR condition. The system passes back through these exchange conditions to the FXL as CR washes out of the tissue. The Fig. S1 curves also depend on the pulse sequence parameters, TR and ␣, which are under operator control. For Fig. S1 a-d, these are 10, 10, 4, and 10 ms, and 10°, 30°, 10°, 30°, respectively. It is clear that the pulse sequence parameters affect the exchange sensitivity (dynamic range between the dotted curves) and the signal strength: the ordinate is the same for each panel.
It is important to note that the (Fig. S1a was extrapolated for the latter) .
The general closeness of the red dotted and black solid Fig. S1 curves suggests that there will not be large parameter value differences when data are analyzed with the FXL-c (SM) and SXR-a (SSM) models. The IDC/DCIS results in Table 1 bear this out. Although the v e value is increased by 31%, the K trans value is increased not at all. As [CR o ] builds, the opposite signs between identical terms on the right-hand sides of Eqs. S4 and S5 mean that the a S S S term begins to partially nullify the a L S L term on the right-hand side of Eq. 2. This dilutes the latter's nonlinear [CR o ] dependence. This is not a problem when the a L S L and a S S S terms can be discriminated (the SXR) and individually fitted (as R 1L and R 1S ) (1).
These curves also suggest why analysis using SXR-a might return a very much larger i value than would analysis using FXR-a. Assume that an actual situation is best represented by the FXR-a blue curve, in Fig. S1b for example-that is, the a S S S term contribution is truly negligible, for some reason. But, in each iteration the data are analyzed with the SXR-a model, which uses the black curve. A way for the black curve to mimic the behavior of the blue curve is to have a i value larger than that of the latter (370 ms). However, the black curve cannot go below its red dotted NXL lower limit. Thus, the i value returned is pegged at the largest value allowed in the computer algorithm. For the data in the main text, this result occurs for 86% of the malignant tumors and for 73% of the benign lesions. An analogous situation may obtain for equilibrium transendothelial water exchange (21) . Simulations confirm that SXR-a analysis of data generated with only S L underestimates K trans and v e , and overestimates i .
Literature Comparison.
It is important to compare the parameter values determined from DCE-MRI pharmacokinetic analyses with independent measures of the same quantities. In general, we find that the FXR-a version of the SSM yields results in quite good agreement with the literature. This usually means that the Standard Model (FXL-c) parameter values do not agree as well. Also, the breast tumor findings presented in this paper suggest that there may be situations where the SXR-a Shutter-Speed version also yields results that include systematic error. The following are surveys for the three parameters often varied in FXR-a SSM analyses.
K trans . The K trans parameter is usually the most precisely determined (Table 1) . It is the most sensitive to the initial slope of the DCE-MRI signal time-course. We are not aware of gold standard K trans measurements for exact CR analogs in solid tumors such as in the breast. At sufficiently high magnetic field, however, CR detectability is sufficiently increased (22) to measure CR extravasation in even normal human brain, where a comparison is available. Thus, an FXR-a (SSM) analysis yields a K trans value of 2.9 ϫ 10 Ϫ5 min Ϫ1 for the Gd(HP-DO3A) CR in normal white matter (23) , in good agreement with gold standard, sacrificial autoradiographic analyses of rodent brain data obtained (at the earth's magnetic field) with radiotracers almost chemically identical to the MRI CR (24, 25) . However, an FXL-constrained (SM) analysis of the same normal white matter MRI data (23) increases K trans to 4.5 ϫ 10 Ϫ5 min Ϫ1 and out of agreement with the tracer results. In this case, the SM raises K trans because the pertinent exchange is equilibrium transendothelial water interchange. Careful analyses of these brain DCE-MRI data demonstrate that the SXR condition is never reached, even during the CR first pass, albeit at half the standard dose (16) . (26) . The malignant tumor v e values returned by FXR-a SSM (9, (26) (27) (28) (29) (30) (31) can sometimes be quite large. However, some time ago, Gullino reported neoplastic solid tumor v e values to be ''very large,'' ranging from 0.2 to 0.5 as determined by classic radioisotope dilution measurements (32) . Note, that except for one malignant tumor [that is mostly benign tissue (33) ], here it is benign lesions that have the larger Fig. 2B SSM v e values. In fact, the mean FXR-a v e value for all seven malignant tumors is 0.59 (Fig. 2B) , at the edge of Gullino's range. Thus, the malignant lesion v e values we report are in rather good agreement with Gullino's survey. In most cases, v e may be related to the tissue ''cellularity'' complement. It is possible, however, that in some very advanced tumors there are regions with significant necrosis and/or cell cytolemmae so compromised that CR enters even the cells. It is also possible that CR enters some mammary duct lumen regions (34) . In cases such as these, the v e parameter is better thought of as an effective CR distribution volume fraction, v D , and not attributed to exclusively interstitial space. Perhaps a number of the benign lesions here are cyst-like.
We suspect, however, that the very large v e values of some benign lesions may be overestimates (i.e., more than just imprecise). The CR uptake in most benign tumors is very slow, reflecting the fact that K trans is small (Fig. 2 A) . Thus, the rise in signal intensity is sufficiently slow that the maximum is usually not reached before DCE-MRI acquisition ceases (Fig. 1D) , and thus the time-course curve is never completely defined. Because v e is most sensitive to the area under the DCE-MRI time-course, it may suffer particularly from this premature pharmacokinetic acquisition period truncation. In a DCE-MRI study of murine implanted RIF-1 tumors, it was found that FXL-c (SM) analyses yielded tumor rim v e values that decreased significantly with increasing CR dose (27) . Of course, the v e value is defined to be a tumor tissue property and should not be dependent on the CR dose or rate of delivery. We had previously shown with first-principle theory and simulation that the assumption of effectively infinitely fast equilibrium transcytolemmal water exchange by the FXL-c model would be manifest as precisely such CR dose dependence (9) . Application of FXR-a (SSM) analyses to the same data eliminated most of the CR dose dependence and yielded constant v e values at Ϸ0.65 (27) . Thus, when not CR dose-quenched, the SM also returns large tumor v e values. Such dose dependence may contribute to literature SM irreproducibility.
i. Often the least precisely determined of the three parameters usually varied in FXR-a DCE-MRI analyses is i (9) . However, a number of recent such studies have reported i values consistently ranging from a few tenths of second to a few seconds, for a wide variety of normal and pathological tissues (9, (26) (27) (28) (29) (30) 35) . These values are in excellent agreement with what one calculates from classic ''gold standard'' physiology. For a spherical cell, ''well-mixed'' theory gives: i ϭ r/(3P W ), where r is the cell radius, and P W is the cytolemmal water permeability coefficient (1) . Taking a ''typical'' spherical parenchymal cell of r ϭ 5 m to have P W ϭ 1.4 ϫ 10 Interstitial Field Inhomogeneities. When a paramagnetic CR is constrained to a vessel lumen, there are significant magnetic field inhomogeneities in the perivascular space (37) . This is visualized, for example, as the ''blooming'' around large cerebral vessels in contrast-enhanced susceptibility-weighted images (38) . At the small (2, 37) peak [CR b ] value of 2.5 mM after the standard dose monomeric Gd(III) chelate bolus injection (Fig. 1D Inset) , the blood susceptibility is Ϫ8.3 ppm (37, 39) . We can use magnetic susceptibility first principles to calculate the magnetic field dispersion just outside the surface of a vessel oriented perpendicular to the main magnetic field to be 0.8 ppm (0.4 to Ϫ0.4), and at a distance of even one vessel radius from the surface to be 0.6 ppm (0.3 to Ϫ0.3) (37, 39) . As shown in the main text, this could cause significant ''quenching'' of the signal from spins in these regions in a clinical DCE-MRI acquisition.
Then, as CR enters the interstitium the susceptibility of the entire interstitium increases, and the difference between that and the cytoplasmic value causes field inhomogeneities that are larger in interstitial spaces. This is predicted by susceptibility first principles (37) and confirmed by MR spectroscopy. In vivo 23 Na o spectral lines are considerably broader than 23 Na i peaks in the presence of interstitial DyTTHA 3Ϫ (40, 41) , and this broadening is caused by susceptibility gradients (40) . These peaks are discriminated because transcytolemmal Na ϩ exchange is quite slow. Because relative susceptibility broadening is independent of the resonant nucleus (37), the same greater broadening (in ppm) will affect the unresolvable interstitial 1 H 2 O resonance. Because the 1 H resonant frequency is approximately 4 times that of 23 Na, the absolute inhomogeneous broadening will be significantly greater for 1 H. Perhaps all of these geometric susceptibility aspects are exacerbated for the abnormal, convoluted neoplastic tumor capillary bed morphology (42) . 
